Phaseline

Companies › Guangzhou Excelmab

Guangzhou Excelmab: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EX103
CD3 and CD20 bispecific monoclonal antibody
CD3E, CD20Phase 1CD20-positive Non-Hodgkin Lymphoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06021678EX103Phase 1CD20-positive Non-Hodgkin LymphomaOncologyOct 2025

Targets

CD3E (1) CD20 (1)

Companies with the same targets

Johnson & Johnson (Janssen) AstraZeneca Roche Regeneron Pharmaceuticals Amgen Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Tiziana Life Sciences Sanofi Shine-On Biomedical Pfizer

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.